*September 2022* From Dr. Julien Mazieres' presentation at ESMO 2022
laurabbook@gmail.comOctober 31, 2022
*September 2022* Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of objective response rate and had a benign safety profile in non–small cell lung cancer with EGFR exon 20 insertion mutations. DZD9008 (sunvozertinib) in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon…
laurabbook@gmail.comOctober 30, 2022
*September 2022* Trastuzumab deruxtecan (Enhertu) demonstrated clinically meaningful benefit and a favorable safety profile at the lower of 2 dose levels in patients with HER2-mutated non–small cell lung cancer (NSCLC), according to interim results of the DESTINY-Lung02 trial (NCT04644237) presented at the 2022 European Society for Medical Oncology (ESMO) Congress.1…
laurabbook@gmail.comOctober 30, 2022
*September 2022* Fine particulate matter from the combustion of fossil fuels seemed to trigger non-small cell lung cancer (NSCLC) in never smokers through a process of "tumor promotion," according to a study on the etiology of EGFR-mutated disease. The link was first suggested decades ago and long overlooked, but now…
laurabbook@gmail.comOctober 30, 2022
*June 2022* Highlights: Alternation of osimertinib and afatinib was evaluated for patients with metastatic treatment-naïve EGFR-mutated NSCLC in this phase 2 trial. Although the 12-month PFS probability was 70.2%, which did not meet the primary end point, the median PFS was 21.3 months suggesting the promising efficacy of this alternative…
laurabbook@gmail.comOctober 30, 2022
*September 2022* Lung cancer specialist Lecia V Sequist, MD, MPH discusses the current and future management of EGFR NSCLC with host Dr. Neal Love. This informative presentation is available in the following formats: video, audio, and powerpoint slides. Listen to the audio/read transcription here. Watch the video/download slides here. Please…
laurabbook@gmail.comOctober 30, 2022
*October 2022* Given all the exciting news out of ESMO about mechanisms of air pollution coupled with EGFR mutation, the GO2 Foundation for Lung Cancer and ALCMI want to re-flag this study! They are hoping to be able to do an interim analysis in time for ASCO 2023 and need…
laurabbook@gmail.comOctober 30, 2022
*August 2022* Alexander I. Spira, MD, PhD, FACP, research institute director, Thoracic and Phase 1 Trial Program, Virginia Cancer Specialists Research Institute, Virginia Cancer Specialists, clinical assistant professor, Johns Hopkins University, discusses additional studies investigating the use of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) in EGFR-mutated non–small cell lung cancer (NSCLC).…
laurabbook@gmail.comSeptember 25, 2022
*August 2022* From WCLC Abstract presented by Dr. Jie Huang Introduction: Small cell lung cancer (SCLC) transformation remains one of the unsettled resistant mechanisms for lung adenocarcinoma (LUAD), of which co-occurring TP53 and RB1 mutations defined a subgroup of patients with increased risk of SCLC transformation. Our study aimed to…
laurabbook@gmail.comSeptember 25, 2022
*August 2022* A total of 77% of women with lung cancer surveyed reported moderate to severe sexual dysfunction, according to results of the SHAWL study presented at the World Conference on Lung Cancer. Of the 127 participants who noted sexual activity in the previous 30 days, 75 (59%) reported significant…
laurabbook@gmail.comSeptember 25, 2022
